Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer
暂无分享,去创建一个
I. Ellis | Simak Ali | S. Shousha | R. Coombes | M. Periyasamy | H. Patel | Chun-Fui Lai | A. Harrod | J. Reményi | F. Fuller-Pace | B. Győrffy | L. Magnani | L. Buluwela | E. Rakha | J. Steel | L. Jones | J. Gomm | N. Patel | Claudia Busonero | C. Gemma | Sally Smith | D. Jerjees | R. Abduljabbar | Balázs Győrffy | Carolina Gemma | Alison Harrod | Hetal Patel
[1] C. Caldas,et al. Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer , 2015, Oncotarget.
[2] I. Ellis,et al. Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer , 2015, Breast Cancer Research and Treatment.
[3] Marion Peyressatre,et al. Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors , 2015, Cancers.
[4] Xin Huang,et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.
[5] D. Heitjan,et al. CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment , 2014, Clinical Cancer Research.
[6] Yan Liu,et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. , 2014, Cancer cell.
[7] Bandana Sharma,et al. CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer , 2014, Cell.
[8] Sridhar Ramaswamy,et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor , 2014, Nature.
[9] I. Ellis,et al. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer , 2014, Breast Cancer Research and Treatment.
[10] D. Rimm,et al. Pin1 modulates ERα levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation , 2014, Oncogene.
[11] Stephen P. Fox,et al. Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells , 2013, Nucleic acids research.
[12] Chun Cheng,et al. Low Expression of CyclinH and Cyclin-Dependent Kinase 7 Can Decrease the Proliferation of Human Esophageal Squamous Cell Carcinoma , 2013, Digestive Diseases and Sciences.
[13] M. Barbacid,et al. Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion , 2012, The EMBO journal.
[14] F. Markowetz,et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.
[15] Karl A. Merrick,et al. Why minimal is not optimal: Driving the mammalian cell cycle—and drug discovery—with a physiologic CDK control network , 2012, Cell cycle.
[16] I. Ellis,et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.
[17] J. Egly,et al. The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process , 2011, The EMBO journal.
[18] L. Murphy,et al. Clinical significance of estrogen receptor phosphorylation. , 2011, Endocrine-related cancer.
[19] A. Thompson,et al. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study , 2010, British Journal of Cancer.
[20] J. Snyder,et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. , 2009, Cancer research.
[21] Li Jia,et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. , 2009, Cancer research.
[22] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[23] B. Ramaswamy,et al. Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant. , 2009 .
[24] G. Ball,et al. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. , 2008, European journal of cancer.
[25] Jérôme Eeckhoute,et al. Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer , 2007 .
[26] C. R. Wilson,et al. Ménage-à-Trois 1 Is Critical for the Transcriptional Function of PPARγ Coactivator 1 , 2007 .
[27] J. Eeckhoute,et al. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. , 2007, Cancer research.
[28] Simak Ali,et al. Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression , 2006 .
[29] G. Shapiro,et al. Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Shousha,et al. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. , 2006, Endocrine-related cancer.
[31] R. Fisher. Secrets of a double agent: CDK7 in cell-cycle control and transcription , 2005, Journal of Cell Science.
[32] M. Barbacid,et al. Mammalian cyclin-dependent kinases. , 2005, Trends in biochemical sciences.
[33] G. Ball,et al. High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.
[34] R. Métivier,et al. Differential Regulation of Estrogen-Inducible Proteolysis and Transcription by the Estrogen Receptor α N Terminus , 2005, Molecular and Cellular Biology.
[35] T. Barrette,et al. Mining for regulatory programs in the cancer transcriptome , 2005, Nature Genetics.
[36] L. Johnson,et al. CAK—Cyclin-Dependent Activating Kinase: A Key Kinase in Cell Cycle Control and a Target for Drugs? , 2005, Cell cycle.
[37] G Leclercq,et al. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer , 2004, Molecular and Cellular Endocrinology.
[38] Simak Ali,et al. Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera , 2002, Oncogene.
[39] M. Barbacid,et al. To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.
[40] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[41] Gregor Mikuz,et al. Ep-CAM overexpression in breast cancer as a predictor of survival , 2000, The Lancet.
[42] P. Chambon,et al. TFIIH Interacts with the Retinoic Acid Receptor γ and Phosphorylates Its AF-1-activating Domain through cdk7* , 2000, The Journal of Biological Chemistry.
[43] Simak Ali,et al. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. , 2000, Molecular cell.
[44] Chawnshang Chang,et al. From Androgen Receptor to the General Transcription Factor TFIIH , 2000, The Journal of Biological Chemistry.
[45] A. Levine,et al. The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro , 1997, Molecular and cellular biology.
[46] P. Chambon,et al. Stimulation of RARα Activation Function AF-1 through Binding to the General Transcription Factor TFIIH and Phosphorylation by CDK7 , 1997, Cell.
[47] J. Bartek,et al. Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell‐cycle position and differentiation , 1996, International journal of cancer.